Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tremelimumab + HDI in advanced melanoma
NCT00610857Phase 2Completed
- Sponsor
- Ahmad Tarhini
- Start
- Nov 2006
- Primary completion
- Jan 2015
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of tremelimumab in melanoma, sponsored by Ahmad Tarhini. Started Nov 2006; status: completed.
02
Drugs
tremelimumab
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00610857.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00610857.